ArticleEClinicalMedicine2021

Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

Nathan W Cummins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.